[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SLC51B

Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass membrane protein Note=Mainly restricted to the lateral and basal membranes of ileal enterocytes.
Domain PF15048 Organic solute transporter subunit beta protein
Function

Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafficking and stability activities.

> Gene Ontology
 
Biological Process GO:0006486 protein glycosylation
GO:0006612 protein targeting to membrane
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0010559 regulation of glycoprotein biosynthetic process
GO:0010560 positive regulation of glycoprotein biosynthetic process
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015721 bile acid and bile salt transport
GO:0015849 organic acid transport
GO:0015850 organic hydroxy compound transport
GO:0031647 regulation of protein stability
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032527 protein exit from endoplasmic reticulum
GO:0033157 regulation of intracellular protein transport
GO:0043413 macromolecule glycosylation
GO:0046942 carboxylic acid transport
GO:0051222 positive regulation of protein transport
GO:0060049 regulation of protein glycosylation
GO:0060050 positive regulation of protein glycosylation
GO:0070085 glycosylation
GO:0070861 regulation of protein exit from endoplasmic reticulum
GO:0070863 positive regulation of protein exit from endoplasmic reticulum
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:0090313 regulation of protein targeting to membrane
GO:0090314 positive regulation of protein targeting to membrane
GO:0090316 positive regulation of intracellular protein transport
GO:1903018 regulation of glycoprotein metabolic process
GO:1903020 positive regulation of glycoprotein metabolic process
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0046982 protein heterodimerization activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04976 Bile secretion
Reactome -
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC51B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC51B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC51B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0920.85
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5290.639
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4610.741
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9370.0852
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8560.426
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.20.364
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1050.915
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1690.896
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6170.00304
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC51B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC51B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC51B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC51B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC51B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC51B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC51B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC51B
Namesolute carrier family 51, beta subunit
Aliases OSTbeta; organic solute transporter beta subunit; OSTB; OST-beta; solute carrier family 51 subunit beta; Org ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC51B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.